Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Accumulated Expenses (2023 - 2025)

Compass Therapeutics (CMPX) has disclosed Accumulated Expenses for 3 consecutive years, with $11.4 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 81.06% to $11.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.4 million through Dec 2025, up 81.06% year-over-year, with the annual reading at $11.4 million for FY2025, 81.06% up from the prior year.
  • Accumulated Expenses hit $11.4 million in Q4 2025 for Compass Therapeutics, up from $2.5 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $11.4 million in Q4 2025 to a low of $1.5 million in Q1 2025.
  • Historically, Accumulated Expenses has averaged $5.4 million across 3 years, with a median of $4.2 million in 2023.
  • Biggest five-year swings in Accumulated Expenses: plummeted 79.7% in 2024 and later skyrocketed 375.02% in 2025.
  • Year by year, Accumulated Expenses stood at $2.5 million in 2023, then skyrocketed by 150.08% to $6.3 million in 2024, then soared by 81.06% to $11.4 million in 2025.
  • Business Quant data shows Accumulated Expenses for CMPX at $11.4 million in Q4 2025, $2.5 million in Q3 2025, and $11.0 million in Q2 2025.